Source:http://linkedlifedata.com/resource/pubmed/id/12969762
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2003-9-12
|
pubmed:abstractText |
Up to now, it is not yet clear whether and how clozapine and its metabolites are metabolized in neuronal cells. The interconversion of clozapine and its metabolites, clozapine-N-oxide and norclozapine, was studied in the hippocampal neuronal in vitro system of HT22 cells. Clinically relevant concentrations of clozapine (200+400 ng/ml) and its metabolites (100+200 ng/ml) were used for the examination of the metabolizing effects after short- (4 h) and long- (24 h) term incubation. Two-way analysis of variance revealed a significant decrease of clozapine (P<0.01) and norclozapine (P<0.01) levels in the supernatants of HT22 cells after the treatment procedures. Student-Newman-Keuls tests showed a significant decrease of clozapine 400 after 24 h of incubation (P=0.01) as well as of all concentrations of norclozapine. No significant treatment effects were found for the clozapine-N-oxide degradation. Using semi-quantification by reverse transcriptase-polymerase chain reaction methods, we could show a significant increase of cytochrome P450 (CYP) 1A2 mRNA levels (P<0.05) after clozapine treatment with 200 ng/ml. The results of the present study strongly suggest that clozapine and norclozapine are metabolized in hippocampal neuronal HT22 cells by CYP1A2, whereas the levels of clozapine-N-oxide were not affected. Moreover, CYP1A2 mRNA levels were significantly changed by incubation with clozapine 200.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Clozapine,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP1A2,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/clozapine N-oxide,
http://linkedlifedata.com/resource/pubmed/chemical/norclozapine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0014-2999
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
29
|
pubmed:volume |
476
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
167-72
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12969762-Analysis of Variance,
pubmed-meshheading:12969762-Biological Transport,
pubmed-meshheading:12969762-Cells, Cultured,
pubmed-meshheading:12969762-Clozapine,
pubmed-meshheading:12969762-Cytochrome P-450 CYP1A2,
pubmed-meshheading:12969762-Hippocampus,
pubmed-meshheading:12969762-Humans,
pubmed-meshheading:12969762-RNA, Messenger,
pubmed-meshheading:12969762-Reverse Transcriptase Polymerase Chain Reaction
|
pubmed:year |
2003
|
pubmed:articleTitle |
Pharmacokinetics of clozapine and its metabolites in hippocampal HT22 cells.
|
pubmed:affiliation |
Department of Child and Adolescent Psychiatry and Psychotherapy, Philipps-University of Marburg, Hans-Sachs-Str 6, 35037 Marburg, Germany. heiser@mailer.uni-marburg.de
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|